Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C38718
http://purl.obolibrary.org/obo/NCIT_C38718
|
|---|---|
| Preferred Name | Axitinib |
| Definitions |
An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect. |
|---|---|
| prefLabel | Axitinib
|
| label | Axitinib
|
| PDQ_Closed_Trial_Search_ID | 352181
|
| code | C38718
|
| Has_Target | |
| prefixIRI | NCIT:C38718
|
| in_subset |
See more
See less
|
| Display_Name | Axitinib
|
| Preferred_Name | Axitinib
|
| FDA_UNII_Code | C9LVQ0YUXG
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C22H18N4OS
|
| Maps_To | Axitinib
|
| CAS_Registry | 319460-85-0
|
| NCI_Drug_Dictionary_ID | 352181
|
| Legacy Concept Name | AG-013736
|
| type | |
| ALT_DEFINITION | A substance that is being studied in the treatment of cancer. It belongs to the families of drugs called angiogenesis inhibitors and protein tyrosine kinase inhibitors.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 352181
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C1700874
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |